SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Sequenom, Inc. , today announced that Paul V. Maier has been appointed as the company’s interim chief financial officer effective November 10, 2009, reporting directly to the company’s interim chief executive officer and chairman of the board, Harry F. Hixson, Jr., Ph.D.
Prior to the effective date of Mr. Maier’s appointment as interim chief financial officer, Mr. Maier will act as a consultant to the company.
Mr. Maier has been an independent financial consultant since February 2007. Mr. Maier served as senior vice president and chief financial officer of Ligand Pharmaceuticals Incorporated from 1992 until January 2007, where he helped build Ligand from a venture stage boutique company to a commercial, integrated biopharmaceutical organization. During his tenure at Ligand, Mr. Maier helped raise over $1 billion in equity and debt financings. Prior to Ligand, Mr. Maier spent six years in various management and finance positions at ICN Pharmaceuticals.
SEQUENOM(R) is a registered trademark of Sequenom, Inc.
CONTACT: Ian Clements, Ph.D., Sr. Director, Corp. Communications, of
Sequenom, Inc., +1-858-202-9000; or investor relations, Jody Cain,
+1-310-691-7100, jcain@lhai.com, of Lippert/Heilshorn & Associates; or
media, Dan Budwick, +1-973-271-6085, of Pure Communications, both for
Sequenom, Inc.
Web site: http://www.sequenom.com/
Company News On-Call: http://www.prnewswire.com/comp/124192.html
